Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
JAK Inhibitors Target Arthritis
by Rick Mullin
November 26, 2012
| A version of this story appeared in
Volume 90, Issue 48
Incyte has earned a $50 million milestone payment from Eli Lilly & Co. for the initiation of Phase III trials on baricitinib, Incyte’s oral treatment for rheumatoid arthritis. Incyte disclosed the payment a week after FDA approved Pfizer’s oral rheumatoid arthritis drug Xeljanz. Both drugs are JAK inhibitors, which target signaling pathways inside cells that play a role in the inflammation involved in arthritis. Pfizer says Xeljanz is the first JAK inhibitor for rheumatoid arthritis and the first new oral rheumatoid drug in more than 10 years.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter